NOCDURNA TREATS THE OVERPRODUCTION OF URINE AT NIGHT BY TARGETING THE KIDNEYS1,2

  • NOCDURNA mimics the body’s natural vasopressin—an antidiuretic hormone that promotes water absorption1

NOCDURNA targets the kidneys—unlike traditional LUTS medications, which target the bladder or prostate4,5

DOSAGE

Designed for targeted dosage

  • Treats the overproduction of urine at night by targeting the kidneys, with specific dosage for men and women1,4
  • Designed to deliver a low and effective dose of desmopressin acetate1
NOCDURNA offers specific doses for men: 55.3 mcg per day

MEN
55.3 mcg/day

WOMEN
27.7 mcg/day

NOCDURNA (desmopressin acetate) sublingual tablets for nocturnal polyuria

Packaging is not actual size.

administration

Take 1 tablet daily, 1 hour before bedtime, without water. Tablet should be kept under the tongue until it has fully dissolved

Sublingual tablet is taken 1 hour
before bedtime without water1

Before starting or resuming NOCDURNA1:

Assess sodium concentration and only start or resume NOCDURNA
in patients with a normal serum sodium concentration

SODIUM MONITORING

  • Ensure serum sodium concentration is normal prior to initiating or resuming NOCDURNA1
    • NOCDURNA is contraindicated in patients with hyponatremia or a history of hyponatremia
  • Check serum sodium concentration within the first week and again at one month after initiating or resuming therapy1
  • Periodically monitor serum sodium during NOCDURNA therapy, as clinically appropriate1
    • More frequent serum sodium monitoring is recommended for patients ≥65 years old and for those at risk of hyponatremia
  • If the patient develops hyponatremia, NOCDURNA may need to be temporarily or permanently discontinued, and treatment for the hyponatremia instituted, depending on the clinical circumstances, including the duration and severity of the hyponatremia1

References: 1. NOCDURNA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Van Kerrebroeck P, Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurouol Urodyn. 2014;33 (Suppl 1):S2-S5. 3. Aditya S, Rattan A. Vaptans: a new option in the management of hyponatremia. Int J Appl Basic Med Res. 2012;2(2):77-83. 4. Weiss JP, van Kerrebroeck PE, Klein BM, et al. Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia. J Urol. 2011;186(4):1358-1363. 5. Weiss JP, Blaivas JG, Bliwise DL, et al. The evaluation and treatment of nocturia: a consensus statement. BJU Int. 2011;108(1):6-21.